Recruiting

Testing a new cancer-fighting medication in advanced solid tumors

Plain-English translation of NCT07224425 on ClinicalTrials.gov ↗ · Source last updated July 2026 · Translation generated August 2026 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

This is one of the first times this treatment has been tested in people.

What is this trial?

This is an early-stage trial testing a new cancer medication called in people with advanced solid tumors (cancers that form in organs or tissues) and melanoma. Researchers want to find the right dose of this medication that patients can safely tolerate, and whether it helps slow or shrink these cancers. The medication is being studied for the first time in humans.

Many patients with advanced cancer have exhausted standard treatment options, and their disease continues to progress. This trial exists to discover whether this new treatment approach might offer hope to patients for whom current therapies are no longer working or don't exist.

Do you qualify?

You likely qualify if…

you have been diagnosed with advanced solid cancer or melanoma that has progressed despite previous treatments or for which no standard treatment exists
you are at least 18 years old
you have a good overall health status and life expectancy of at least 3 months, as determined by your doctor
you have at least one measurable tumor that can be tracked with imaging
you have adequate organ function and any side effects from previous cancer treatments have mostly resolved
your BRAF mutation status (for melanoma patients in Part B) is known before screening

You likely don't qualify if…

you have active or untreated brain cancer or cancer that has spread to your brain with symptoms
you have a weakened immune system or are taking immune-suppressing medications (with some exceptions for low-dose steroids)
you have received another cancer drug within the past 4 weeks or extensive radiation therapy within the past 2 weeks
you have received more than 3 previous lines of cancer treatment (though some prior treatments may not count)

What participation looks like

You will receive as an injection or infusion, typically once every 3 weeks, though you may start with weekly doses at the beginning. Early study visits will include overnight hospital stays so doctors can closely monitor your safety. Throughout the trial, you'll have regular visits to the study site for blood tests, health checks, and imaging scans to measure your tumor size. You can continue receiving the medication as long as you're benefiting from it, but treatment will not continue beyond 2 years.

AI-generated summary from trial data · Aug 2, 2026 · Not medical advice

Testing a new cancer-fighting medication in advanced solid tumors

What is this trial?

Do you qualify?

What participation looks like

Trial locations